已收盘 04-02 16:00:00 美东时间
+0.043
+6.03%
今日重点评级关注:Maxim Group:上调Theriva Biologics评级至"买入",目标价1美元;HC Wainwright & Co.:维持Bicara Therapeutics"买入"评级,目标价从40美元升至42美元
04-01 16:34
HC Wainwright & Co. analyst Yi Chen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.5.
03-31 19:04
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 43.48 percent increase over losses of $(0.46) per share from the
03-23 20:54
Envoy Medical completes enrollment for its Acclaim cochlear implant trial, a fully implanted device designed without external components.
03-11 19:46
Envoy Medical (NASDAQ:COCH) announced on Tuesday that Nasdaq notified the company it had regained compliance with Listing Rule 5550(b)(2) under alternatives permitted by Rule 5550(b). The company said...
02-24 21:40
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen TaylorClosing of $30 million in gross proceeds in upsized offering, with up to an
02-19 21:07
Envoy Medical shares are trading higher after the company announced pricing of ...
02-12 03:35
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational
2025-12-18 21:12
Momentum continues to build for Company as series of clinical milestones are met, design choices cement differentiation from competition, and timeline comes into focusWhite Bear Lake, Minnesota--(Newsfile Corp. -
2025-12-10 21:11
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the
2025-11-20 21:10